Traders should monitor for the interim pharmacodynamic readout at ~12 weeks (expected late Q3 2026) as the next catalyst; the reduced trial size may lower capital needs, but no funding or revenue implications are confirmed. Absent clinical data or approval, near-term stock movement may be limited.
Price Chart
Executive Summary
Medicus Pharma announced the submission of an optimized Phase 2 clinical trial design for Teverelix, its investigational GnRH antagonist, to the FDA for the prevention of recurrent acute urinary retention (AURr) in men with BPH. The redesigned trial reduces patient enrollment to ~126 and focuses on early pharmacodynamic signals, aiming to accelerate development and enable faster partnering discussions. No clinical data or FDA decision has been issued yet—this is a forward-looking development update.
Key Facts
- Medicus Pharma submitted an optimized Phase 2 study design for Teverelix to the FDA for AURr in BPH patients.
- The trial (ANT-2111-02) will enroll ~126 patients across the U.S. and Europe in a randomized, double-blind, four-arm design.
- Primary endpoint: percent change in total prostate volume (TPV) at Week 12; interim analysis expected after 50% of patients complete Week 12.
- Study includes single-dose arms of Teverelix 90 mg (IM) and 120 mg (SC), with placebo controls; all patients remain on alpha-blockers.
- No clinical results or FDA approval decision announced—this is a protocol submission, not a trial outcome.
Financial Impact
No immediate financial impact disclosed; potential long-term value if trial succeeds in a $2B underserved market.
Risk Factors
- No guarantee the FDA will accept the study design or that the trial will yield positive results.
- Company has multiple non-binding collaborations (HelixNano, Reliant AI, GSA) with no assurance of definitive agreements.
- Market cap of $9M reflects high risk; lack of approved products and reliance on future clinical outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268361 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.60 | awaiting T+1 | — | $2.42 (−6.92%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.42 (−8.85%) |
Oct 16, 2026 10d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.42 (−8.85%) |
Oct 7, 2026 19d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.42 (+2274.88%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.42 (+1419.15%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.42 (−1388.31%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.42 (+1399.38%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.42 (+1319.35%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.42 (+496.06%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.42 (−703.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers